Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Cogent Biosciences, Inc. (COGT) had Normalized Income after Taxes of $-97.35M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-97.35M |
|
-- |
|
-- |
|
$103.61M |
|
$-103.61M |
|
$6.25M |
|
$-97.35M |
|
$-97.35M |
|
$-97.35M |
|
$-97.35M |
|
$-97.35M |
|
|
Normalized Income after Taxes |
$-97.35M |
$-103.61M |
|
$-103.88M |
|
162.19M |
|
162.19M |
|
$-0.53 |
|
$-0.53 |
|
| Balance Sheet Financials | |
$877.80M |
|
$5.30M |
|
$25.20M |
|
$903.01M |
|
$57.98M |
|
$223.17M |
|
$237.33M |
|
$295.31M |
|
$542.94M |
|
$607.69M |
|
$607.69M |
|
170.77M |
|
| Cash Flow Statement Financials | |
$-86.88M |
|
$-36.46M |
|
$52.54M |
|
$312.43M |
|
$241.62M |
|
$-70.80M |
|
$16.91M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.14 |
|
-- |
|
-- |
|
0.27 |
|
0.37 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-87.33M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-17.93% |
|
-16.02% |
|
-10.78% |
|
-11.72% |
|
$3.56 |
|
$-0.54 |
|
$-0.54 |
|